期刊名：Antibodies

期刊主页：https://www.mdpi.com/journal/antibodies

本期编辑荐读为您精选2024-2025年发表于 Antibodies 期刊的十篇高引文章。希望能为相关领域学者提供新的思路和参考，欢迎阅读。

1. Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria

灾难性抗磷脂综合征的诊断与管理及 2023 年 ACR/EULAR 抗磷脂综合征分类标准的潜在影响

https://www.mdpi.com/2073-4468/13/1/21

Jacobs, L.; Wauters, N.; Lablad, Y.; Morelle, J.; Taghavi, M. Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Antibodies 2024, 13, 21.

2. Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database

PD-1、PD-L1、CTLA-4 和 LAG-3 免疫检查点抑制剂的不良事件：基于 FDA 不良事件数据库的分析

https://www.mdpi.com/2073-4468/13/3/59

Frey, C.; Etminan, M. Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database. Antibodies 2024, 13, 59.

3. Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment

免疫细胞衔接器：推进癌症治疗的精准免疫疗法

https://www.mdpi.com/2073-4468/14/1/16

In, H.; Park, M.; Lee, H.; Han, K.H. Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment. Antibodies 2025, 14, 16.

4. Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules

银屑病治疗进展：从生物制剂到新兴口服小分子药物

https://www.mdpi.com/2073-4468/13/3/76

Ferrara, F.; Verduci, C.; Laconi, E.; Mangione, A.; Dondi, C.; Del Vecchio, M.; Carlevatti, V.; Zovi, A.; Capuozzo, M.; Langella, R. Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules. Antibodies 2024, 13, 76.

5. Unveiling GFAP Astrocytopathy: Insights from Case Studies and a Comprehensive Review of the Literature

揭示GFAP星形胶质细胞病：病例研究的启示和文献综述

https://www.mdpi.com/2073-4468/13/4/79

Gklinos, P.; Athanasopoulos, F.; Giatrakou, V.; Arkoudis, N.-A.; Pournara, D.; Giagkou, E.; Tountopoulou, A.; Vassilopoulou, S.; Mitsikostas, D.-D. Unveiling GFAP Astrocytopathy: Insights from Case Studies and a Comprehensive Review of the Literature. Antibodies 2024, 13, 79.

6. A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments

CCR4靶向疗法在皮肤T细胞淋巴瘤中的前沿进展综述：聚焦莫格利珠单抗与未来治疗方向

https://www.mdpi.com/2073-4468/13/2/32

Zengarini, C.; Guglielmo, A.; Mussi, M.; Motta, G.; Agostinelli, C.; Sabattini, E.; Piraccini, B.M.; Pileri, A. A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments. Antibodies 2024, 13, 32.

7. Immune-Mediated Necrotizing Myopathy (IMNM): A Story of Antibodies

免疫介导性坏死性肌病（IMNM）：抗体的研究历程

https://www.mdpi.com/2073-4468/13/1/12

Julien, S.; Challier, I.; Malleter, M.; Jouen, F.; Drouot, L.; Boyer, O. Immune-Mediated Necrotizing Myopathy (IMNM): A Story of Antibodies. Antibodies 2024, 13, 12.

8. Avian Antibodies as Potential Therapeutic Tools

禽类抗体作为潜在的治疗工具

https://www.mdpi.com/2073-4468/14/1/18

Eriksson, M.; Larsson, A. Avian Antibodies as Potential Therapeutic Tools. Antibodies 2025, 14, 18.

9. TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth

利用特异性抗体阻断TLR2和TLR9可抑制炎症介导的胰腺癌细胞生长

https://www.mdpi.com/2073-4468/13/1/11

Ajay, A.K.; Gasser, M.; Hsiao, L.-L.; Böldicke, T.; Waaga-Gasser, A.M. TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth. Antibodies 2024, 13, 11.

10. 50 Years of Antibody Numbering Schemes: A Statistical and Structural Evaluation Reveals Key Differences and Limitations

抗体编号方案五十年发展历程：统计和结构评估揭示关键差异和局限性

https://www.mdpi.com/2073-4468/13/4/99

Zhu, Z.; Olson, K.S.; Magliery, T.J. 50 Years of Antibody Numbering Schemes: A Statistical and Structural Evaluation Reveals Key Differences and Limitations. Antibodies 2024, 13, 99.

Antibodies期刊介绍

主编：Arne Skerra, Technical University of Munich, Germany

期刊主题涵盖抗体和体液免疫反应、抗体的发现、产生和选择、抗体结构和功能、抗体工程、结合物和融合蛋白、生物医学研究和治疗中的抗体。

2025 Impact Factor: 3.3

2025 CiteScore: 4.9

Time to First Decision: 22.7 Days

Acceptance to Publication: 4.8 Days